Л. Г. Фечина
A5076227272- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Neuroblastoma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Adolescent and Pediatric Healthcare
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- DNA Repair Mechanisms
- Prenatal Screening and Diagnostics
- Brain Metastases and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Gene expression and cancer classification
- Pharmacological Effects and Toxicity Studies
Institute of Medical Cell Technologies
2014-2025
Regional Children's Clinical Hospital No. 1
2014-2025
Regional Children's Hospital No1
2014-2020
Ural Federal University
2017
Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present data obtained from 2345 leukemia patients. Genomic breakpoints within MLL involved translocation partner genes (TPGs) were determined 11 novel TPGs identified. Thus, a total 135 different have been identified so far, which 94 now characterized at molecular level. In all, 35 out these occur recurrently, but only 9 specific fusions account for...
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize chromosomal rearrangement individual leukemia patients. present data molecular characterization 1590 MLL-rearranged biopsy samples obtained from The precise localization genomic breakpoints within involved translocation partner genes (TPGs) were determined...
Abstract Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well therapy-induced infant, pediatric, and adult acute leukemias. Here, we present data obtained from 3401 leukemia patients that have been analyzed between 2003 2022. Genomic breakpoints within KMT2A involved translocation partner genes (TPGs) -partial tandem duplications (PTDs) were determined. Including published literature, a total 107 in-frame fusions identified so far. Further 16...
We report incidence and deep molecular characteristics of lineage switch in 182 pediatric patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were treated with blinatumomab. documented six cases that occurred after or during blinatumomab exposure. Therefore, conversion was found 17.4% all resistance (4/27) 3.2% relapses (2/63). Half switched completely from BCP-ALL to CD19-negative myeloid leukemia, others retained CD19-positive B-blasts acquired an additional...
The main goal of L-asparaginase therapy in acute lymphoblastic leukemia (ALL) is complete depletion asparagine the blood and cerebrospinal fluid, accompanied by death tumor blasts. Asparagine difficult to measure reliably due its rapid degradation ex vivo. Serum asparaginase activity correlates well with depletion. International guidelines clearly state need for therapeutic drug monitoring (TDM) improve clinical outcomes treatment patients ALL. aim article describe adaptation method...
We developed and implemented in multicenter setting the standardized approach for flow cytometric minimal residual disease (MRD) monitoring childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Participation of group reference laboratories several ring trial studies demonstrated high concordance rate between participants. Successful integration one additional laboratory has shown good level our reproducibility. These results will allow implementing MRD detection stratification...
The aim of this study was to present the diagnostic and outcome characteristics infants with germline status KMT2A gene (KMT2A-g) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated consistently according MLL-Baby protocol, a moderate-intensity protocol. Of 139 patients enrolled in study, 100 (71.9%) carried different types rearranged (KMT2A-r), while remaining 39 (28.1%) had KMT2A-g. KMT2A-g were generally older (77% than 6 months), less likely have very high white blood cell...
Abstract Sequential monitoring of minimal residual disease (MRD) by molecular techniques or multicolor flow cytometry (MFC) has emerged over the past two decades as primary tool to optimize treatment in pediatric B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). The aim our study was compare prognostic power repeated MFC–MRD measurement with single‐point MRD assessment children BCP‐ALL treated reduced‐intensity protocol ALL‐MB 2008. Data from consecutive at day 15 and 36 (end...
Abstract Background Detection of bone marrow (BM) involvement in patients with neuroblastoma is crucial for staging and defining prognosis. Furthermore, the persistence residual tumor cells BM associated an unfavorable outcome. Methods Expression PHOX2B , TH ELAVL4 B4GALNT1 (GD2‐synthase) was analyzed by quantitative polymerase chain reaction cell lines, control samples, samples from patients. The threshold level expression each gene established through receiver operator characteristic...
Favorable outcomes were achieved for children with acute lymphoblastic leukemia (ALL) the first Russian multicenter trial Moscow–Berlin (ALL-MB) 91. One major component of this regimen included a total 18 doses weekly intramuscular (IM) native Escherichia coli-derived asparaginase (E. coli-ASP) at 10000 U/m2 during three consolidation courses. ASP was initially available from Latvia, but had to be purchased abroad substantial costs after collapse Soviet Union. Therefore, subsequent ALL-MB...
Minimal residual disease (MRD) monitoring by flow cytometry at the end of induction therapy is one key ways a prognosis assessment in patients with acute lymphoblastic leukemia (ALL). In B-cell precursor ALL (BCP–ALL), this method MRD detection complicated due to immunophenotypic similarity between leukemic cells and normal precursors (BCPs). A decrease intensity can lead more frequent appearance BCPs bone marrow, which significantly complicates monitoring. Aim: assess incidence marrow on...
Abstract Background Quantitative measurement of minimal residual disease (MRD) is the “gold standard” for estimating response to therapy in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). Nevertheless, speed MRD differs different cytogenetic subgroups. Here we present results children with BCP‐ALL, terms genetic subgroups relation clinically defined risk groups. Methods A total 485 non‐high‐risk BCP‐ALL available data and studied at end‐of‐induction (EOI) by multicolor...
Summary The prognostic value of minimal residual disease (MRD) measured by fusion‐gene transcript (FGT) detection was investigated in 76 infants (aged ≤1 year) with acute lymphoblastic leukaemia (ALL) lysine methyltransferase 2A ( KMT2A ) rearrangements. Either at the end induction or later time‐points, FGT‐MRD‐positivity associated poor outcome. after first consolidation high‐risk block detected 46·5% extremely outcome [disease‐free survival (SE) 0·06 (0·06), cumulative incidence relapse...
Summary This study aimed to evaluate the concordance between minimal residual disease (MRD) results obtained by multicolour flow cytometry (MFC) and polymerase chain reaction for fusion gene transcripts (FGTs) in infants with acute lymphoblastic leukaemia (ALL) associated rearrangement of KMT2A ( ‐r). A total 942 bone marrow (BM) samples from 123 were studied MFC‐MRD FGT‐MRD. In total, 383 (40.7%) concordantly MRD‐negative. MRD was detected two methods 441 cases (46.8%); 99 (10.5%) only...
Serious side effects occur during therapy for childhood acute lymphoblastic leukemia (ALL), and survivors can experience long-term consequences. This study aimed at identifying patients who be successfully treated with low treatment intensity combining clinical parameters minimal residual disease (MRD) measurements. The was approved by the Independent Ethics Committee Scientific Council of Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. ALL-MB...